Janux Therapeutics, Inc. (JANX) · INSIDERData sourcesSEC Form 45h ago
House PTR5h ago
SEC 13F5h ago
Robinhood Chain5h ago
Public companyJanux Therapeutics, Inc.
JANXCIK 0001817713
Price$17.63
1 year-36.0%
Disclosed transactions25
Buys / sells0 / 9
Max Insider Score40
Connections with evidence9
JANX · disclosed activity on price
| Score | Actor | Security | Side | Value | Executed | Disclosed | Lag | Source | Evidence |
|---|
| 28 | DNDoyle Janeen NoelChief Corp. & Bus. Dev. Ofcr | JANXJanux Therapeutics, Inc. Open-market sale | SELL | $57K 4,059 sh | Jun 2, 2026 |
| Jun 4, 2026 traded Jun 2, 2026 |
| 21 | DMDobek MariaVice President, Accounting | JANXJanux Therapeutics, Inc. Open-market sale | SELL | $29K 2,038 sh | May 11, 2026 | May 13, 2026 traded May 11, 2026 | +2d | SEC Form 4 | |
| 9 | GWGo WilliamChief Medical Officer | JANXJanux Therapeutics, Inc. Grant or award | A | — 44.0K sh | Feb 2, 2026 | Feb 4, 2026 traded Feb 2, 2026 | +2d | SEC Form 4 | |
| 9 | GWGo WilliamChief Medical Officer | JANXJanux Therapeutics, Inc. Grant or award | A | — 154.0K sh | Feb 2, 2026 | Feb 4, 2026 traded Feb 2, 2026 | +2d | SEC Form 4 | |
| 36 | DTDiRaimondo ThomasChief Scientific Officer | JANXJanux Therapeutics, Inc. Open-market sale | SELL | $34K 2,505 sh | Jan 2, 2026 | Jan 2, 2026 traded Jan 2, 2026 | +0d | SEC Form 4 | |
| 39 | CACampbell David AlanDirector, President and CEO | JANXJanux Therapeutics, Inc. Open-market sale | SELL | $111K 8,072 sh | Jan 2, 2026 | Jan 2, 2026 traded Jan 2, 2026 | +0d | SEC Form 4 | |
| 32 | MHMeyer Andrew HollmanChief Business Officer | JANXJanux Therapeutics, Inc. Open-market sale | SELL | $26K 1,879 sh | Jan 2, 2026 | Jan 2, 2026 traded Jan 2, 2026 | +0d | SEC Form 4 | |
| 9 | CACampbell David AlanDirector, President and CEO | JANXJanux Therapeutics, Inc. Grant or award | A | — 338.1K sh | Jan 2, 2026 | Jan 2, 2026 traded Jan 2, 2026 | +0d | SEC Form 4 | |
| 9 | MZMcIver ZachariahChief Medical Officer | JANXJanux Therapeutics, Inc. Grant or award | A | — 101.5K sh | Jan 2, 2026 | Jan 2, 2026 traded Jan 2, 2026 | +0d | SEC Form 4 | |
| 21 | MZMcIver ZachariahChief Medical Officer | JANXJanux Therapeutics, Inc. Grant or award | A | — 29.0K sh | Jan 2, 2026 | Jan 2, 2026 traded Jan 2, 2026 | +0d | SEC Form 4 | |
| 36 | WMWinter Charles M.Chief Technical Officer | JANXJanux Therapeutics, Inc. Open-market sale | SELL | $33K 2,401 sh | Jan 2, 2026 | Jan 2, 2026 traded Jan 2, 2026 | +0d | SEC Form 4 | |
| 17 | WMWinter Charles M.Chief Technical Officer | JANXJanux Therapeutics, Inc. Grant or award | A | — 28.6K sh | Jan 2, 2026 | Jan 2, 2026 traded Jan 2, 2026 | +0d | SEC Form 4 | |
| 9 | WMWinter Charles M.Chief Technical Officer | JANXJanux Therapeutics, Inc. Grant or award | A | — 100.1K sh | Jan 2, 2026 | Jan 2, 2026 traded Jan 2, 2026 | +0d | SEC Form 4 | |
| 17 | CACampbell David AlanDirector, President and CEO | JANXJanux Therapeutics, Inc. Grant or award | A | — 96.6K sh | Jan 2, 2026 | Jan 2, 2026 traded Jan 2, 2026 | +0d | SEC Form 4 | |
| 9 | DTDiRaimondo ThomasChief Scientific Officer | JANXJanux Therapeutics, Inc. Grant or award | A | — 109.9K sh | Jan 2, 2026 | Jan 2, 2026 traded Jan 2, 2026 | +0d | SEC Form 4 | |
| 9 | DNDoyle Janeen NoelChief Corp. & Bus. Dev. Ofcr | JANXJanux Therapeutics, Inc. Grant or award | A | — 126.0K sh | Jan 2, 2026 | Jan 2, 2026 traded Jan 2, 2026 | +0d | SEC Form 4 | |
| 40 | DMDobek MariaVice President, Accounting | JANXJanux Therapeutics, Inc. Open-market sale | SELL | $20K 1,462 sh | Jan 2, 2026 | Jan 2, 2026 traded Jan 2, 2026 | +0d | SEC Form 4 | |
| 21 | DNDoyle Janeen NoelChief Corp. & Bus. Dev. Ofcr | JANXJanux Therapeutics, Inc. Grant or award | A | — 36.0K sh | Jan 2, 2026 | Jan 2, 2026 traded Jan 2, 2026 | +0d | SEC Form 4 | |
| 40 | MZMcIver ZachariahChief Medical Officer | JANXJanux Therapeutics, Inc. Open-market sale | SELL | $37K 2,714 sh | Jan 2, 2026 | Jan 2, 2026 traded Jan 2, 2026 | +0d | SEC Form 4 | |
| 21 | DMDobek MariaVice President, Accounting | JANXJanux Therapeutics, Inc. Grant or award | A | — 18.9K sh | Jan 2, 2026 | Jan 2, 2026 traded Jan 2, 2026 | +0d | SEC Form 4 | |
| 9 | DMDobek MariaVice President, Accounting | JANXJanux Therapeutics, Inc. Grant or award | A | — 42.6K sh | Jan 2, 2026 | Jan 2, 2026 traded Jan 2, 2026 | +0d | SEC Form 4 | |
| 17 | DTDiRaimondo ThomasChief Scientific Officer | JANXJanux Therapeutics, Inc. Grant or award | A | — 31.4K sh | Jan 2, 2026 | Jan 2, 2026 traded Jan 2, 2026 | +0d | SEC Form 4 | |
| 0 | MHMeyer Andrew HollmanChief Business Officer | JANXJanux Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $35K 3,333 sh | Nov 14, 2025 | Nov 14, 2025 traded Nov 14, 2025 | +0d | SEC Form 4 | |
| 8 | MHMeyer Andrew HollmanChief Business Officer | JANXJanux Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $100K 3,333 sh | Nov 14, 2025 | Nov 14, 2025 traded Nov 14, 2025 | +0d | SEC Form 4 | |
| 0 | MHMeyer Andrew HollmanChief Business Officer | JANXJanux Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 3,333 sh | Nov 14, 2025 | Nov 14, 2025 traded Nov 14, 2025 | +0d | SEC Form 4 | |
Chief Medical Officer · Jan 2, 2026